**Core Concept**
Behcet syndrome is a form of vasculitis characterized by a complex interplay of immune-mediated inflammation and endothelial damage, leading to various systemic manifestations including mucocutaneous lesions, ocular involvement, and vascular complications. The pathogenesis involves a dysregulated immune response, with activation of T cells, macrophages, and the complement system.

**Why the Correct Answer is Right**
The treatment of Behcet syndrome is primarily focused on managing symptoms and preventing complications. **Corticosteroids** are often used to reduce inflammation and suppress the immune response. **Immunosuppressive agents**, such as cyclophosphamide, azathioprine, or methotrexate, may be added to control disease activity and prevent relapses. In cases of severe ocular involvement, **biologics** like infliximab or adalimumab may be considered to target specific cytokines involved in the inflammatory process.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect as it does not address the complex pathophysiology of Behcet syndrome and the need for a multi-modal treatment approach.
* **Option B:** This option is incorrect as it does not mention the use of corticosteroids or immunosuppressive agents, which are essential components of Behcet syndrome treatment.
* **Option D:** This option is incorrect as it does not provide a clear treatment approach and may be too broad or nonspecific.

**Clinical Pearl / High-Yield Fact**
In Behcet syndrome, the use of corticosteroids and immunosuppressive agents can help control disease activity, but may also increase the risk of infections and other side effects. Therefore, careful monitoring and individualized treatment planning are crucial to optimize patient outcomes.

**Correct Answer:** C. Corticosteroids and immunosuppressive agents, with possible biologic therapy for severe ocular involvement.